Earnings ·
uniQure N.V. reported second quarter 2026 financial results and provided a corporate update on July 29, 2026
QUREuniQure N.V.
uniQure N.V. reported second quarter 2026 financial results and provided a corporate update on July 29, 2026. The company generated $5.8 million in revenue and recorded a net loss of $81.1 million, or $1.22 per share, compared to a $37.7 million loss in the prior year period. Cash reserves increased to $810.3 million following the June 2026 closing of a $259 million follow-on equity offering at $45.50 per share, extending the cash runway into 2030. Regulatory progress includes alignment with the FDA on a Biologics License Application (BLA) for AMT-130 for Huntington’s disease, with submission expected in Q3 2026 and four-year clinical data to be presented in September. Additionally, preliminary data for AMT-260 showed seizure reductions in epilepsy patients, while development of AMT-191 for Fabry disease remains paused pending evaluation of liver enzyme elevations. uniQure N.V. operates as a gene therapy company developing transformative treatments for severe genetic diseases.